Searched for
CLINICAL TRIALS INDUSTRY
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- UnitedHealth’s $3 billion AI push has bots calling doctorsThe largest US health insurer plans to invest $3 billion in AI over 2026 and 2027. UnitedHealth executives say they’re seeing a 2-to-1 retu...
- Business lesson from world's first trillionaire Elon Musk: 'Rely less on business gurus and their books and more on biographies' What business owners can learn from world's richest man's success mindsetElon Musk, the world's first trillionaire, eschews traditional business gurus, drawing wisdom from history and biographies of innovators. H...
- Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform globalPrecision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Drug companies directed to step up vigil on adverse reactionsIndia's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Novo Nordisk uses AI to fast-track drug launches, expand India roleNovo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...
- Want to jump into the 'China is back' rally? Tread carefullyInvestors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...
- Quote of the Day by Franz Kafka: 'You can hold yourself back from the sufferings of the world, that is...'—Top quotes by the Absurdist fiction novelist, author of The MetamorphosisQuote of the Day: Franz Kafka, a renowned writer, explored themes of isolation and anxiety. His quote suggests that avoiding the world's su...
- Drugmakers must report safety data from launch date, not approval date: CDSCOIndia's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be su...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- ET Most Innovative AI Product Awards 2026: Honouring AI Innovations reshaping Life Sciences & Pharma ResearchThe Life Sciences & Pharma category at the ET Most Innovative AI Product Awards 2026. Recognises organisations leveraging AI to accelerate ...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- India on the verge of becoming clinical trials hub, Parexel executive saysIndia is poised to become a prominent site for early-stage clinical trials, particularly amid the disruptions caused by the Russia-Ukraine ...
- India emerging as a hub for clinical trials, says Parexel"In the past, if they wanted to do clinical trials in 28 countries, India used to be 20th on the list. But, now, India started popping up a...
- Can clinical trials rebound in India? Upcoming rules, court case to set the road of recoveryThough Indian clinical-trial industry is ailing, it can get better. An ongoing court case and upcoming new rules will determine the arc of ...
- In India, if there's element of doubt then you are seen as guilty: Dennis Gillings, CEO, Quintiles"We and our customers are nervous about the climate of clinical research in India, and we are not expanding and pausing to see how things g...
- Govt not to allow trials for drugs developed outside IndiaThe health ministry will put on hold its plans to grant permissions to multinational pharma firms for conducting phase I clinical trials of...
Load More
